Published in

American Society for Microbiology, Journal of Virology, 7(95), 2021

DOI: 10.1128/jvi.02260-20

Links

Tools

Export citation

Search in Google Scholar

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice

Journal article published in 2021 by Juan García-Arriaza ORCID, Urtzi Garaigorta ORCID, Patricia Pérez, Adrián Lázaro-Frías, Carmen Zamora, Pablo Gastaminza, Carlos del Fresno, José M. Casasnovas, Carlos Óscar S. Sorzano, David Sancho, Mariano Esteban
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The continuous dissemination of the novel emerging SARS-CoV-2 virus, with more than 78 million infected cases worldwide and higher than 1,700,000 deaths as of 23 December 2020, highlights the urgent need for the development of novel vaccines against COVID-19. With this aim, we have developed novel vaccine candidates based on the poxvirus modified vaccinia virus Ankara (MVA) strain expressing the full-length SARS-CoV-2 spike (S) protein, and we have evaluated their immunogenicity in mice using DNA/MVA or MVA/MVA prime/boost immunization protocols.